Author

Olga Popova

Hospital Universitario de La Princesa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A G Shatalov· 1 shared Alexander L. Gintsburg· 1 shared Anastasia N. Zolotar· 1 shared Andrei E. SiniaviniD· 1 shared Arántzazu AlfrancaiD· 1 shared Denis A. KleymenoviD· 1 shared Denis Y. LogunoviD· 1 shared Egor Y. Bogdanov· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A G Shatalov

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

IFI16/AIM2 inflammasomes control Gal-9 and PVR in myeloid cells from PWH and their targeting improves immunotherapy against HIV-1

Marta Calvet‐Mirabent, Ilya Tsukalov, Ildefonso Sánchez‐Cerrillo, Jesus Pino-Platas, Paul Nicholas Holmes-Anton, María Agudo-Lera, Olga Popova, Raquel González, Lucio Jesus García-Fraile, José Antonio Lebrón-Romero, Manuel López‐López, Sergio Serrano-Villar, Santiago Moreno, Pilar López‐Cornejo, Francisco Sánchez‐Madrid, , Enrique Martín‐Gayo

The paper shows that inhibiting IFI16 and AIM2 in myeloid cells from HIV-1 patients reduces Gal-9 and PVR, enhancing CD8+ T-cell responses against HIV-1.

bioRxiv · Jan 28, 2026 · PreprintImmunology

Comparison candidate Tick-borne encephalitis virus vaccines based on mRNA, adenovirus serotype 25 and chimera of YFV vaccine strain

Nadezhda A. Kuznetsova, Vladimir А. Gushchin, Elizaveta V. Marchuk, Andrei E. Siniavin, Denis A. Kleymenov, Maria A. Nikiforova, Olga V. Zubkova, Olga Popova, Вавилова Ирина Викторовна, Tatiana A. Ozharovskaia, Elena P. Mazunina, Evgeniia N. Bykonia, Egor Y. Bogdanov, Anastasia N. Zolotar, Elena V. Shidlovskaya, , Alexander L. Gintsburg

This study compares three TBEV vaccine candidates—mRNA-LNP, recombinant adenovirus, and YFV chimera—and finds the mRNA-LNP vaccine has higher immunogenicity and protective efficacy in mice.

bioRxiv · Jan 16, 2025 · PreprintImmunology